No licensed hantavirus vaccine exists as of May 2026, with most candidates still in preclinical development or early Phase 1 trials that have not yet advanced to later-stage testing required for regulatory approval. Recent Andes virus outbreaks, including a 2026 cruise-ship cluster with confirmed cases and fatalities, have heightened urgency and prompted additional research funding, yet experts note that full clinical progression, safety data review, and manufacturing scale-up typically require several more years absent an Operation Warp Speed-style acceleration. Trader consensus at 91.5% probability of “No” aligns with these timelines and historical patterns for rare-disease vaccines, where sporadic incidence limits commercial incentives. A realistic challenge to this outlook would require rapid Phase 2/3 results, emergency-use authorization, or major new government investment before year-end.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,800 Vol.
$92,800 Vol.
Dec 31, 2026
$92,800 Vol.
$92,800 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists as of May 2026, with most candidates still in preclinical development or early Phase 1 trials that have not yet advanced to later-stage testing required for regulatory approval. Recent Andes virus outbreaks, including a 2026 cruise-ship cluster with confirmed cases and fatalities, have heightened urgency and prompted additional research funding, yet experts note that full clinical progression, safety data review, and manufacturing scale-up typically require several more years absent an Operation Warp Speed-style acceleration. Trader consensus at 91.5% probability of “No” aligns with these timelines and historical patterns for rare-disease vaccines, where sporadic incidence limits commercial incentives. A realistic challenge to this outlook would require rapid Phase 2/3 results, emergency-use authorization, or major new government investment before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Pasar Dibuka: May 4, 2026, 10:39 AM ET
Volume
$92,800Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists as of May 2026, with most candidates still in preclinical development or early Phase 1 trials that have not yet advanced to later-stage testing required for regulatory approval. Recent Andes virus outbreaks, including a 2026 cruise-ship cluster with confirmed cases and fatalities, have heightened urgency and prompted additional research funding, yet experts note that full clinical progression, safety data review, and manufacturing scale-up typically require several more years absent an Operation Warp Speed-style acceleration. Trader consensus at 91.5% probability of “No” aligns with these timelines and historical patterns for rare-disease vaccines, where sporadic incidence limits commercial incentives. A realistic challenge to this outlook would require rapid Phase 2/3 results, emergency-use authorization, or major new government investment before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$92,800Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine exists as of May 2026, with most candidates still in preclinical development or early Phase 1 trials that have not yet advanced to later-stage testing required for regulatory approval. Recent Andes virus outbreaks, including a 2026 cruise-ship cluster with confirmed cases and fatalities, have heightened urgency and prompted additional research funding, yet experts note that full clinical progression, safety data review, and manufacturing scale-up typically require several more years absent an Operation Warp Speed-style acceleration. Trader consensus at 91.5% probability of “No” aligns with these timelines and historical patterns for rare-disease vaccines, where sporadic incidence limits commercial incentives. A realistic challenge to this outlook would require rapid Phase 2/3 results, emergency-use authorization, or major new government investment before year-end.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan